近年来,基于肿瘤抗原的单克隆抗体为基础的免疫疗法进展迅速。诸如美罗华(rituximab)、赫赛汀(trastuzumab)和西妥昔单抗(cetuximab)等药物,已应用于临床治疗恶性淋巴瘤、乳腺癌、头颈部癌和结肠癌等[1-3]。单克隆抗体免疫治疗可以单独使用,但临床通常与放疗和(或)化疗联用,且临床疗效显著提高[4]:初治患者治愈率提高,复发或转移患者的总生存期延长。放疗或化疗联用西妥昔单克隆抗体、赫赛汀、美罗华时, In recent years, based on the tumor antigen monoclonal antibody-based immunotherapy is progressing rapidly. Drugs such as rituximab, trastuzumab and cetuximab have been used clinically for the treatment of malignant lymphoma, breast cancer, head and neck cancer and colon cancer [1-3]. Monoclonal antibody immunotherapy can be used alone, but the clinical usually associated with radiotherapy and / or chemotherapy, and significantly improved clinical efficacy [4]: ​​the cure rate of patients with early treatment increased recurrence or metastasis in patients with extended survival. Radiotherapy or chemotherapy combined with cetuximab, Herceptin, Rituximab,